![consumerism](jpg/healthcare_consumer-e1478497357270-150x150.jpg)
News
-
HHS Issues Proposal Bolstering Nondiscrimination Protections For People With Disabilities
HHS released a new proposed rule to update nearly 50-year old regulations protecting people with disabilities from discrimination while seeking healthcare. With its new proposal, HHS is amending the regulations to be clearer in their language, as well as more aligned with the Americans with Disabilities Act, the Americans with Disabilities Amendments Act and amendments to the Rehabilitation Act.
-
Seagen and Nurix Join Forces to Develop a New Class of Cancer Medicines
Seagen and Nurix are bringing their respective technologies together to develop a new class of cancer drugs called degrader antibody conjugates. Nurix CEO Arthur Sands says the multi-year, multi-target collaboration expands the reach of each company’s technology.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
4 Steps Needed to Improve Patient Safety On a National Level, Per PCAST
The President’s Council of Advisors on Science and Technology (PCAST) issued a report that laid out four recommendations to improve patient safety across the nation. Some of these included creating federal leadership positions focused on advancing patient safety and hastening research on systems of safe care.
-
Devices & Diagnostics, Health Tech
Abbott-Bigfoot Deal Proves That Diabetes Is a Hot Area for Digital Health Investment
This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.
-
Artificial Intelligence, BioPharma
Recursion Vets Unveil Startup Noetik, Using AI to Unlock Tumor Biology
By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.
-
Orphan Drug Development Is Next for Tech to Tackle
Drug developers need policies and technological infrastructure to execute on their goal of being patient-focused. At a minimum, this means a compliant way to engage patients and truly hear their voices; at its most effective, patient engagement also meets patients where they are – whenever and wherever that may be.
-
Integral Snags $7M In Seed Funding for Its Healthcare Data Privacy Platform
Integral raked in $6.9 million in seed funding in this week. The San Francisco-based startup is developing technology that seeks to speed up the process of exchanging sensitive health data while still maintaining robust privacy protection.
-
3 Ways to Use an Engineering Mindset to Optimize Patient Access Workflows
In a day of vast innovation, expansion, and acquisitions, an engineering mindset can bring a unique and effective approach to thinking across the system, evaluating the current and future state, standardizing on best practices, and considering upstream and downstream workflows.
-
How Pitango VC Is Planning to Invest Its New $175M Health Tech Fund
Pitango Venture Capital, one of the largest venture capital firms in Israel, announced the first closing of a new $175 million healthcare technology fund. With the new fund, the firm plans to build a portfolio of approximately 15 new companies over a period of three to four years.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Delivering Precision Care to Manage Neurodegenerative Diseases
Precision medicine for neurodegenerative conditions has the potential to radically change the way patients are treated and managed over time. As an industry, we must continue to expand our thinking and push the boundaries of science, technology, and data analytics to capture precision medicine opportunities in broader areas of unmet medical needs.
-
A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
-
Nestlé Sells Peanut Allergy Drug, Ending the Food Giant’s Foray Into Biotech
Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic.
-
HHS Will Likely Face More Lawsuits Against Drug Price Negotiation Now That It Has Named the First 10 Meds Included In the Plan
Novartis became the seventh drugmaker to legally challenge the White House’s Medicare drug pricing negotiation program. The company filed its lawsuit three days after HHS announced the first 10 drugs that were selected for the program — its heart failure medication Entresto was one on the list. HHS can expect to face more lawsuits from the manufacturers of the 10 drugs it named last week, experts have warned.
-
Nursing Homes Reject CMS’ Proposed Staffing Level Requirements
CMS released a proposed rule to establish staffing standards among the nation’s nursing homes. Reactions have been mixed — but mainly negative. Long-term care facilities say that they can neither find nor afford more workers. On the other hand, some lawmakers argue the proposed rule doesn’t do enough to protect care quality for patients. As for labor unions, they seem generally happy with the rule.
-
Star Therapeutics Lands $90M to Expand Its Drug Discovery Universe
Startup Star Therapeutics will use the Series B funding to support clinical development of a drug candidate for von Willebrand disease, a bleeding disorder. The capital will also support the formation of new biotech subsidiaries developing antibodies with therapeutic applications in hematology and immunology.
-
Health IT, MedCity Influencers
Taming the Healthcare Data Beast: Conquering Complexity for Better Care
By following these foundational data best practices, healthcare organizations will harness the power of their data to provide superior patient care while safeguarding patient privacy and compliance.
-
Twice Rejected Diabetes Drug/Device Product Gets New Chance at Startup i2o
Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2o Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.
-
How Will Generative AI Change the Role of Clinicians In the Next 10 Years?
A new report predicted that generative AI tools will increasingly streamline many aspects of a clinician’s day in the next five to 10 years — and that this is particularly true for tools that can automate diagnoses and respond to patients’ questions.